OGT to host Webinar on the optimal strategies for exome sequencing
Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, will host a live Webinar on Thursday 6th September (3 pm BST) hosted by Dr Daniel Swan, Senior NGS Computational Biologist at OGT. Entitled “Exome sequencing and analysis strategies that deliver meaningful results”, the Webinar will provide insight and advice for optimising exome sequencing studies, taking advantage of the knowledge and experience routinely offered as part of OGT’s comprehensive Genefficiency™ exome sequencing and analysis service. The Webinar will be ideal viewing for any clinical or genomic researchers interested in learning how to best utilise the power offered by next generation sequencing analysis.
Exome sequencing is fast becoming the technique of choice to identify the novel genetic variations underpinning a variety of conditions, from rare diseases to cancer. However, effective study design and data analysis strategies are essential to ensure the delivery of meaningful results. The live Webinar will provide insight into running a successful exome sequencing project, including the advantages of exome sequencing, considerations for effective study design, crucial data analysis optimisation steps and effective analysis workflows for different sample types (e.g. rare disease, trios and cancer samples).
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
Notes for editors:
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative genetics research and biomarker solutions to advance molecular medicine. The company has two trading businesses: Genomics comprises of CytoSure™ cytogenetics array, labelling and interpretation software products and services for the detection of chromosomal abnormalities, and Genefficiency™ Genomic Services, a unique combination of platforms, expertise and processing capabilities to deliver rapid, relevant genomic data. The Biomarkers business utilises proprietary next generation technologies to build a rich patent-protected portfolio of promising biomarkers for early stage cancer detection including advanced programmes in colorectal and prostate cancer plus the autoimmune disease systemic lupus erythematosus.
CytoSure™ and Genefficiency™ NGS browser: For Research Use Only; Not for Use in Diagnostic Procedures
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.